Achilles Therapeutics PLC ADR (ACHL)vsRegeneron Pharmaceuticals Inc (REGN)
ACHL
Achilles Therapeutics PLC ADR
$1.48
0.00%
HEALTHCARE · Cap: $63.22M
REGN
Regeneron Pharmaceuticals Inc
$904.35
+0.16%
HEALTHCARE · Cap: $95.99B
Smart Verdict
WallStSmart Research — data-driven comparison
REGN leads profitability with a 28.5% profit margin vs 0.0%. REGN earns a higher WallStSmart Score of 78/100 (B+).
ACHL
Avoid32
out of 100
Grade: F
REGN
Strong Buy78
out of 100
Grade: B+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ACHL.
Margin of Safety
+39.8%
Fair Value
$1500.88
Current Price
$904.35
$596.53 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Strong operational efficiency at 40.5%
Revenue surging 36.3% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Keeps 29 of every $100 in revenue as profit
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Expensive relative to growth rate
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ACHL
The strongest argument for ACHL centers on Price/Book, Debt/Equity.
Bull Case : REGN
The strongest argument for REGN centers on Operating Margin, Revenue Growth, Debt/Equity. Profitability is solid with margins at 28.5% and operating margin at 40.5%. Revenue growth of 36.3% demonstrates continued momentum.
Bear Case : ACHL
The primary concerns for ACHL are Revenue Growth, EPS Growth, Altman Z-Score.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Piotroski F-Score.
Key Dynamics to Monitor
ACHL profiles as a value stock while REGN is a growth play — different risk/reward profiles.
ACHL carries more volatility with a beta of 1.25 — expect wider price swings.
REGN is growing revenue faster at 36.3% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
REGN scores higher overall (78/100 vs 32/100), backed by strong 28.5% margins and 36.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Achilles Therapeutics PLC ADR
HEALTHCARE · BIOTECHNOLOGY · USA
Achilles Therapeutics Plc, a clinical-stage immuno-oncology biopharmaceutical company, develops precision T-cell therapies to treat various types of solid tumors. The company is headquartered in London, the United Kingdom.
Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?